Results published in Diabetes Care demonstrate that the Podimetrics SmartMat detected as many as 97% of developing nontraumatic plantar foot ulcers on average five weeks before they presented clinically.
Type B aortic dissection (TBAD) patients exhibit poor adherence to best medical therapy, which may play a part in the high levels of aortic morbidity and mortality seen in this patient cohort, according to research presented by Colin Bicknell (London, UK) at the 2017 Critical Issues meeting (19–20 May, Nuremberg, Germany).
LimFlow announced on 1 August 2017 publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in the July issue of the Journal of Endovascular Therapy. The paper is entitled “Midterm Outcomes from a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia.” The LimFlow System is a novel, purely percutaneous device for the treatment of end-stage critical limb ischaemia (CLI) when all other revascularisation efforts have been exhausted.
Positive two-year clinical data from Endologix’ Nellix EVAS FORWARD investigative device exemption trial have been presented at the Society of Vascular Surgery (SVS; 31 May–3 June) 2017 annual meeting. The trial prospectively enrolled patients with abdominal aortic aneurysms (AAA) who were treated with the Nellix endovascular aneurysm sealing system.
The US Patent and Trademark Office has granted Ra Medical Systems a broad patent (number 9700655) that covers Ra Medical Systems’ DABRA catheter for cardiovascular disease treatment. The inventors include Ra Medical Systems director of research and development, James Laudenslager, and chief executive officer and chief technical officer, Dean Irwin. DABRA recently received FDA market clearance and is now available in the USA and Europe.
Shockwave Medical has announced two milestones for its Lithoplasty system for the treatment of calcified plaque in patients with peripheral artery disease (PAD): enrolment of the first patient in the global DISRUPT PAD III clinical trial at the Medical University of Graz, Austria, and the treatment of the first patient in a commercial case in the USA, at Pottstown Memorial Medical Center in Pottstown.
Silk Road Medical has received US$47 million in new funding led by new investors Norwest Venture Partners and funds managed by Janus Capital Management LLC. Existing investors Warburg Pincus, The Vertical Group, and CRG also participated in the round. The new financing will be used to support the company’s rapid commercial growth of its proprietary ENROUTE family of products for transcarotid artery revascularisation (TCAR) procedures.
Spectranetics has announced receipt of US Food and Drug Administration (FDA) pre-market approval of the Stellarex drug-coated balloon (DCB), designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral artery disease (PAD).
A US study based on the largest representative sample of e-cigarette users to date has provided evidence that e-cigarette use is associated with an increase in smoking cessation at the population level.
A surgical-first strategy appears to be superior to endovascular treatment for critical limb ischaemia revascularisation, exhibiting improved wound healing rate and overall healing time, according to data presented by Jin Okazaki (Kitakyushu, Japan) at the Vascular Annual Meeting (VAM; 30 May–3 June, San Diego, USA).
Surmodics has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a pivotal clinical trial of the SurVeil drug-coated balloon (DCB). The randomised trial will evaluate the SurVeil DCB for treatment for peripheral artery disease (PAD) in the upper leg compared to the IN.PACT Admiral DCB (Medtronic).
A large study of the outcomes of 3,033 patients undergoing lower extremity bypass has reported a 10.6% infection rate and identified procedural risk factors. As reported in the June edition of the Journal of Vascular Surgery, vascular surgeon Peter Henke and researchers from the University of Michigan, Ann Arbor, USA, used data from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium Vascular Intervention Collaborative (BMC2 VIC) to carry out the study.
TVA Medical has announced the online publication of positive results from the Novel Endovascular Access Trial (NEAT) evaluating its everlinQ endoAVF system. The 12-month data published online in the American Journal of Kidney Diseases (AJKD), the official journal of the National Kidney Foundation, demonstrate the potential benefit of the novel approach to create haemodialysis access as an alternative to traditional open surgery.
The UK’s Information Commissioner’s Office (ICO) has found that the Royal Free National Health Service (NHS) Foundation Trust (London, UK) did not adhere to the UK’s Data Protection Act when it provided patient details to Google DeepMind.
Public Health England (PHE) and the Royal Society for Public Health (RSPH) have published “Everyday Interactions”, a report which aims to support healthcare professionals to record and measure their public health impact.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos